Biopharma buffer solutions are aqueous solutions used for controlling and maintaining the pH during several biopharmaceutical processes. Commonly used buffers in the biopharmaceutical industry include phosphate, acetate, borate, and citrate buffers. The biopharma buffer solutions find wide applications in cell culture media, chromatographic running solutions, vaccine formulations, and other biochemical processes performed for drug manufacturing. The continuous growth of the biopharmaceutical industry and increasing demand for biologic drugs have propelled the biopharma buffer market. Advancements in continuous subcutaneous insulin infusion technologies enabling efficient delivery of insulin for diabetes management have also contributed to market growth.

Get more insights on- Biopharma Buffer Market

 

The Global Biopharma Buffer Market is estimated to be valued at US$ 4.24 Bn in 2024 and is expected to exhibit a CAGR of 11.% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the Biopharma Buffer Market are Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, Novo Nordisk, Companion Medical Inc., Jiangsu Deflu Medical Device Co. Ltd., Medtronic PLC, Pendiq GmbH, Sanofi, Berlin Chemie Companion Medical Inc., Bigfoot Biomedical, Digital Medics Pty ltd, Eli Lilly and company, Ypsomed Holding AG, Diabnext Diamesco Co. Ltd.

Key opportunities in the market include increasing investments in R&D of biologic drugs and growing adoption of continuous subcutaneous insulin infusion devices.

Advancements in continuous subcutaneous insulin infusion technologies such as miniature insulin infusion pumps are allowing more efficient delivery of insulin and better management of diabetes.

Market Drivers

The growing prevalence of chronic diseases such as diabetes and cancer is a key driver of the Biopharma Buffer Market Size. Biologic drugs are increasingly being used for treatment of these diseases, fueling the demand for biopharma buffer solutions. According to International Diabetes Federation, around 537 million adults were living with diabetes in 2021 worldwide. Growing geriatric population also contributes to the rising disease burden. Furthermore, advancement in insulin delivery technologies and availability of economical continuous glucose monitoring systems are supporting the uptake of continuous subcutaneous insulin infusion promoting market growth.